Aspirin for primary prevention of cardiovascular disease events

Pharmacotherapy

Volumn 32, Issue 11, 2012, Pages 1020-1035

  Nemerovski, Carrie W ^a   Salinitri, Francine D ^b,c   Morbitzer, Kathryn A ^b   Moser, Lynette R ^b,d  

^a HENRY FORD HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c OAKWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^d HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Aspirin; Cardiovascular disease; Cardiovascular disease prevention; Primary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DIPYRIDAMOLE; PLACEBO; SIMVASTATIN;

ABDOMINAL AORTA ANEURYSM; AGE DISTRIBUTION; ARTICLE; ATHEROSCLEROSIS; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DEATH; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLAUDICATION; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIABETES MELLITUS; DRUG EFFICACY; FRAMINGHAM RISK SCORE; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HEMODIALYSIS; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LEG ISCHEMIA; LOW DRUG DOSE; LOW RISK POPULATION; META ANALYSIS (TOPIC); MONOTHERAPY; NONFATAL MYOCARDIAL INFARCTION; NONFATAL STROKE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PRIMARY PREVENTION; RENAL REPLACEMENT THERAPY; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM; SECONDARY PREVENTION; SEX DIFFERENCE; THROMBOSIS; TREATMENT INDICATION; WOMEN'S HEALTH;

ASPIRIN; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE INHIBITORS; EVIDENCE-BASED MEDICINE; FEMALE; HEMORRHAGE; HUMANS; MALE; META-ANALYSIS AS TOPIC; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SEX CHARACTERISTICS;

EID: 84871571056     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1127     Document Type: Article

References (81)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012;125:e2-220
2. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002;106:388-91 (Pubitemid 34778969)
3. Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American College of Chest Physicians evidenced-based clinical practice guidelines (8th edition). Chest 2008;133:199S-233
4. Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update. J Am Coll Cardiol 2011;58:2432-46
5. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-470
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high cholesterol in adults (adult treatment panel III) final report. Circulation 2002;106:3143-421
7. Calonge N, Petitti DB, DeWitt TG, et al. Aspirin for the prevention of cardiovascular disease: U.S. preventive services task force recommendation statement. Ann Intern Med 2009;150:396-404
8. Berger JS, Jordan CO, Lloyd-James D, Blumenthal RS. Screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol 2010;55:1169-77
9. Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. J Am Coll Cardiol 2009;54:1209-27
10. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds risk score for men Circulation 2008;118:2243-51
11. Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish heart health extended cohort (SHHEC). Heart 2007;93:172-6 (Pubitemid 46180289)
12. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication. The Framingham study. Stroke 1994;25:40-3
13. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003 (Pubitemid 36712275)
14. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007;335:136
15. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008;336:1475-82 (Pubitemid 351977019)
16. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10- year follow-up of the Prospective Cardiovascular Munster (PROCAM) study. Circulation 2002;105:310-5 (Pubitemid 34106178)
17. Mosca L, Linfante AH, Benjamin EJ, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005;111:499-510 (Pubitemid 40204436)
18. Persson M, Carlberg B, Tavelin B, Lindholm LH. Doctors' estimation of cardiovascular risk and willingness to give drug treatment in hypertension: fair risk assessment but defensive treatment policy. J Hypertens 2004;22:65-71 (Pubitemid 38293532)
19. K/DOQI Workgroup. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43(5 suppl 1):S1-290
20. Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: American College of Chest Physicians evidence-based clinical practice guidelines (9th edition). Chest 2012;141:e637S-68
21. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice Eur J Cardiovasc Prev Rehabil 2007;14(suppl 2):S1-113
22. Bell AD, Roussin A, Cartier R, et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. Can J Cardiol 2011;27:S1-59
23. Hammond EC, Garfinkel L. Aspirin and coronary heart disease: findings of a prospective study. Br Med J 1975;2:269-71
24. Hennekens CH, Karlson LK, Rosner B. A case-control study of regular aspirin use and coronary deaths. Circulation 1978;58:35-8 (Pubitemid 8376656)
25. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988;296:313-6 (Pubitemid 18042841)
26. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing physicians' health study. N Engl J Med 1989;321:129-35
27. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:233-41
28. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial. Lancet 1998;351:1755-62 (Pubitemid 28269185)
29. Collaborative Group of the Primary Prevention Project (PPP) Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 2001;357:89-95
30. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304
31. Kjeldsen SE, Warnold I, Hansson L. Influence of gender on prevention of myocardial infarction by antihypertnesives and acetylsalicylic acid: the HOT study. J Gend Specif Med 2000;2:35-8
32. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet 2009;373:1849-600
33. Dorresteijn JA, Visseren FL, Ridker PM, et al. Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects. Eur Heart J 2011;32:2962-9
34. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men. A sex specific meta-analysis of randomized controlled trials. JAMA 2006;295:306-13
35. Spranger M, Aspey BS, Harrison MJ. Sex differences in antithrombotic effect of aspirin. Stroke 1989;20:34-7 (Pubitemid 19040210)
36. Gurm PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-5 (Pubitemid 32721947)
37. Dorsch MP, Lee JS, Lynch DR, et al. Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. Ann Pharmacother 2007;41:737-41 (Pubitemid 46752652)
38. Cavallari LH, Helgason CM, Brace LD, Viana MAG, Nutescu EA. Sex differences in the antiplatelet effect of aspirin in patients with stroke. Ann Pharmacother 2006;40:812-7 (Pubitemid 43764997)
39. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women 2011 updtate: a guideline from the American Heart Association. Circulation 2011;123:1243-62
40. Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions Diabetes Care 2009;32:531-40
41. Pignone M, Williams CD. Aspirin for primary prevention of cardiovascular disease in diabetes mellitus. Nat Rev Endocrinol 2010;11:619-28
42. Natarajan A, Zaman AG, Marchall SM. Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diab Vasc Dis Res 2008;5:138-44 (Pubitemid 351839287)
43. Saco M, Pellegrini F, Roncaglioni MC, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients. Diabetes Care 2003;26:3264-72
44. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: early treatment diabetic retinopathy study report 14. JAMA 1992;268:1292-300
45. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a18400
46. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes. JAMA 2008;300:2134-41
47. Zhang C, Sun A, Zhang P, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a metaanalysis Diabetes Res Clin Pract 2010;87:211-8
48. Calvin AD, Aggarwal NR, Murad MH, et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 2009;32:2300-6
49. De-Berardis G, Sacco M, Strippoli GFM, et al. Aspirin for primary prevention of cardiovascular events in people with diabe- tes: meta-analysis of randomized controlled trials. BMJ 2009;339:b4531
50. Butalia S, Leung AA, Ghali WA, Rabi DM. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and metaanalysis Cardiovasc Diabetol 2011;10:25
51. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007;30:162-72 (Pubitemid 46052519)
52. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 2010;33:1395-402
53. American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care 2012;35:1S11-S63
54. Rooke T, Hirsch A, Misra S, et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline). Circulation 2011;124:2020-45
55. Fowkes FGR, Price JF, Stewart MCW, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index. JAMA 2010;303:841-8
56. Catalano M, Born G, Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med 2007;261:276-84
57. Berger J, Krantz M, Kittelson J, et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009;301:1909-19
58. Raju N, Sobieraj-Teague M, Hirsh J, O'Donnell M. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med 2011;124:621-9
59. Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2011;107:1796-801
60. Seshasai S, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes. Arch Intern Med 2012;172:209-16
61. K/DOQI Workgroup. K/DOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49:S12-154
62. Wali R. Aspririn and the prevention of cardiovascular disease in chronic kidney disease. J Am Coll Cardiol 2010;56:966-8
63. Yerkey MW, Kernis SJ, Franklin BA, Sandberg KR, McCullough PA. Renal dysfunction and acceleration of coronary disease Heart 2004;90:961-6 (Pubitemid 39005960)
64. Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004;30:579-89 (Pubitemid 39426390)
65. Jardine M, Ninomiya T, Perkovic V, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol 2010;56:956-65
66. Baigent C, Landray M, Leaper C, et al. First United Kingdom heart and renal protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 2005;45:473-84 (Pubitemid 40341326)
67. Holden RM, Harman GJ, Want M, Holland D, Day AG. Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:105-10
68. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005;45:s1-153
69. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86
70. Montalescot G, Maclouf J, Drobinski G, Salloum J, Grosgogeat Y, Thomas D. Eicosanoid biosynthesis in patients with stable angina: beneficial effects of very low dose aspirin. J Am Coll Cardiol 1994;24:33-8 (Pubitemid 24202773)
71. Ridker PM, Hennekens CH, Tofler GH, Lipinska I, Buring JE Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women. J Cardiovasc Risk 1996;3:209-12 (Pubitemid 26266495)
72. Cambell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease. A systematic review. JAMA 2007;297:2018-240
73. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after nonurgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122-6 (Pubitemid 38353000)
74. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993;71:397-403
75. Sheps SG, Black HR, Cohen JD, et al. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46
76. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003 (Pubitemid 34286536)
77. Fox KM, Bertrand M, Ferrari R, et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo- controlled, multicenter trial (the EUROPA study). Lancet 2003;362:782-8 (Pubitemid 37093919)
78. Gupta MK, Ostrovski I, Kajil M, Tsigoulis M, Verma S. Who receives ASA for primary prevention in Canada?: insight from the primary care audit of global risk management (PARADIGM) study. Can J Cardiol 2011;27(suppl S):68S
79. Bayer; Bayer Consumer Care Inc. A study to assess the efficacy and safety of enteric-coated acetylsalicylic acid in patients at moderate risk of cardiovascular disease (ARRIVE). Clinical- Trials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/ NCT00501059 Accessed January 22, 2012
80. De Berardis G, Sacco M, Evangelista V, et al. Aspirin and simvastatin combination for cardiovascular events prevention trial in diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 2007;8:21
81. British Heart Foundation; University of Oxford. ASCEND: A study of cardiovascular events in diabetes. ClinicalTrials.gov Bethesda, MD: National Library of Medicine. Available from http://www.clinicaltrials.gov/ct2/show/ NCT00135226. NCT00 135226. Accessed January 22, 2012